Patent Assignment Details
NOTE:Results display only for issued patents and published applications.
For pending or abandoned applications please consult USPTO staff.
|
| Reel/Frame: | 050799/0458 | |
| Pages: | 3 |
| | Recorded: | 10/23/2019 | | |
| Attorney Dkt #: | 52186-700 |
| Conveyance: | CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). |
|
|
Total properties:
7
|
|
|
|
Patent #:
|
|
Issue Dt:
|
09/17/2019
|
Application #:
|
15525836
|
Filing Dt:
|
05/10/2017
|
|
Publication #:
|
|
Pub Dt:
|
03/07/2019
| | | | |
|
Title:
|
FACTOR IX GENE THERAPY
|
|
|
|
|
Patent #:
|
|
Issue Dt:
|
08/31/2021
|
Application #:
|
15573203
|
Filing Dt:
|
11/10/2017
|
|
Publication #:
|
|
Pub Dt:
|
04/26/2018
| | | | |
|
Title:
|
FABRY DISEASE GENE THERAPY
|
|
|
|
|
Patent #:
|
|
Issue Dt:
|
09/17/2019
|
Application #:
|
15573350
|
Filing Dt:
|
11/10/2017
|
|
Publication #:
|
|
Pub Dt:
|
04/26/2018
| | | | |
|
Title:
|
CAPSID
|
|
|
|
|
Patent #:
|
|
Issue Dt:
|
11/24/2020
|
Application #:
|
16105583
|
Filing Dt:
|
08/20/2018
|
|
Publication #:
|
|
Pub Dt:
|
02/20/2020
| | | | |
|
Title:
|
FACTOR IX ENCODING NUCLEOTIDES
|
|
|
|
|
Patent #:
|
|
Issue Dt:
|
12/06/2022
|
Application #:
|
16398840
|
Filing Dt:
|
04/30/2019
|
|
Publication #:
|
|
Pub Dt:
|
02/20/2020
| | | | |
|
Title:
|
FACTOR IX ENCODING NUCLEOTIDES
|
|
|
|
|
Patent #:
|
NONE
|
Issue Dt:
|
|
Application #:
|
16541516
|
Filing Dt:
|
08/15/2019
|
|
Publication #:
|
|
Pub Dt:
|
03/12/2020
| | | | |
|
Title:
|
CAPSID
|
|
|
|
|
Patent #:
|
|
Issue Dt:
|
05/31/2022
|
Application #:
|
16563193
|
Filing Dt:
|
09/06/2019
|
|
Publication #:
|
|
Pub Dt:
|
12/26/2019
| | | | |
|
Title:
|
FACTOR IX GENE THERAPY
|
|
|
Assignee
|
|
|
|
|
| THE NETWORK BUILDING |
| 97 TOTTENHAM COURT ROAD |
| LONDON, UNITED KINGDOM W1T 4TP |
|
|
Correspondence name and address
|
| |
WILSON SONSINI GOODRICH & ROSATI
|
| |
650 PAGE MILL ROAD
|
| |
PALO ALTO, CA 94304-1050
|
Search Results as of:
06/01/2024 08:35 AM
If you have any comments or questions concerning the data displayed,
contact
PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified:
August 25, 2017 v.2.6
| 
